Stay up to date on the latest oncology and nursing conferences.
Best Practices on Managing AEs With Darolutamide Plus ADT/Docetaxel in mHPSC
Data presented during the ONS Annual Congress offers guidance for nurses caring for patients receiving darolutamide, docetaxel, and androgen deprivation therapy.
Jessica MacIntyre on Improving LLS Referrals For Patients With Hematologic Malignancies
Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.
Cardiac Event Management Is a Key Aspect of Safely Treating Patients With Ribociclib in Advanced Breast Cancer
Rita Deimler, MSN, ANP-BC, outlines best cardiac event monitoring and management practices for patients receiving the CDK4/6 inhibitor ribociclib.
Recognizing Maladaptive Coping and Building Resilience in Oncology Nursing Is Vital
Acknowledging and addressing maladaptive coping mechanisms may help reduce moral distress and burnout among oncology nurses.
Stephanie Jackson on Improving the Double Verification Process For High-Alert Medications
Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, highlights how her unit leveraged an educational video to improve compliance with double verification for high-alert medications.
Eric Zack on Disseminated Intravascular Coagulation Prevention and Management
Eric Zack, DNP, RN, ACNP-BC, AOCN, BMTCN, describes disseminated intravascular coagulation and best nursing strategies to mitigate the severity of this condition.
Avasopasem Manganese Significantly Reduces IMRT-Induced Severe Oral Mucositis, Is Feasible in Clinical Workflow
Elizabeth R. Cullen, MSN, ARNP, highlights the efficacy of avasopasem manganese in mitigating severe oral mucositis in patients with locally advanced head and neck cancer.
Ocular Toxicity Management Is Paramount for Mirvetuximab Soravtansine Treatment
Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.
Cilta-Cel AEs Remain Consistent and Manageable for Patients with Multiple Myeloma
An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.
Nurses Call for More Research on Nutrition Challenges for Patients With AML/MDS
Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.
Donna Catamero Discusses Managing Teclistamab-Induced CRS for Patients With Multiple Myeloma
Donna Catamero, ANP-BC, OCN, CCRC, outlines best management strategies for treating patients receiving teclistamab who experience cytokine release syndrome.
Monitoring CRS With Teclistamab Is a Priority in Caring for Patients With Multiple Myeloma
Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.
Radiation Therapy Adverse Effect Management Requires Long-term Monitoring
Ashley Marenyi, RN, BSN, OCN, highlights the importance of counseling patients with head and neck cancer on the short-term and long-term adverse effects of radiation treatment.
Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs
Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.
mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma
Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.
Pembrolizumab in Addition to Cisplatin and Gemcitabine Boosts Overall Survival in Advanced Biliary Tract Cancer
Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.
Genome-Wide Methylome Enrichment Testing Demonstrates High Detection Rate in Early-Stage Cancers With Limited ctDNA
A genome-wide methylome enrichment platform may help identify multiple early-stage cancers.
Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Outperforms Placebo in Resectable NSCLC
The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.
CDCT1 Testing Study Highlights Pitfalls in Current NCCN Genetic Condition Screening Guidelines
Findings from the TAPESTRY trial showed that approximately 40% of patients with genetic conditions may be missed by current NCCN guidelines.
Adjuvant Atezolizumab/Bevacizumab Shows Recurrence-Free Survival Benefit Over Active Surveillance in HCC
Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.
Meghan Berkenstock on Managing Ocular Toxicities With ADCs in Cervical and Ovarian Cancers
Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.
Adding Pembrolizumab to SOC Reduces Risk of Disease Progression or Death in dMMR/pMMR Advanced Endometrial Cancer
Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.
Mary Katherine Montes de Oca on Cryocompression Therapy For Peripheral Neuropathy in Gynecologic Cancers
Mary Katherine Montes de Oca, MD, discusses the potential benefit of cryocompression therapy in preventing peripheral neuropathy in patients with gynecologic cancers who are receiving chemotherapy.
Lindsay Diamond Discusses Ongoing Role of Immunotherapy in Bladder Cancer
Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.
Hyperthermic Intraperitoneal Chemotherapy is Not Associated With Worse HRQOL in Ovarian Cancer
Patients with ovarian cancer who received hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not experience worse health-related quality of life, according to investigators.
Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study
Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.
Lenvatinib Plus Pembrolizumab Elicits Durable Responses in Patients With Endometrial Cancer
In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.
Carolina Frailty Index Score May Be Applicable in Assessment of Patients with Ovarian Cancer
Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer.
GCLQ and LELSQ Show Concordance in Assessment of Lymphedema in Patients With Endometrial Cancer
The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512